Furthermore, since the increased expression of PD-L1 in tumor cells and the stromal compartment is an indicator of a better response rate to immune checkpoint blockade therapies, the observed induction of PD-L1 could provide a potential strategy to augment the benefit of immunotherapies through the conditioning of the TME with HDACi [57,58]. Here, CD274 is linked to neoplasm.